The road to adding a prescription drug benefit to Medicare is
getting bumpier.
The New York Times reports Aug. 27 that legislative negotiations
to offer prescription drugs to Medicare patients have been stalled
because of squabbling between two key lawmakers.
The House and the Senate passed separate versions of the drug
proposals in June and a Capitol Hill committee has been trying to
iron out the differences. But, as the Times notes, "agreements have
been elusive, even on issues listed as noncontroversial."
The Heritage Foundation won't go into the politics of the matter.
We will, however, get into the policy. And one of our policy
recommendations for these bills is this: Start over again.
Sure, some provisions are worth keeping, such as a House proposal
to have competing health plans in Medicare (though not until
2010!). But overall the Medicare drug bills are "full of nasty
surprises," according to Heritage health-care expert Robert Moffit.
Take this one: The Congressional Budget Office estimates the Senate
bill would lead more than 4 million retirees to lose the private
drug coverage they now enjoy and be dumped into Medicare.
Moffit suggests lawmakers take a step back and start again, this
time speeding up reforms based on the successful Federal Employee
Health Benefits Program (FEHBP). The program offers patient choice
(and prescription drugs) to 9 million federal employees and
retirees.
Report Health Care Reform
Medicare Malady #33: A Modest Proposal for the Drug Bill Deadlock
August 28, 2003 1 min read
Download Report
The Heritage Foundation
Authors
The Heritage Foundation
Exclusive Offers
5 Shocking Cases of Election Fraud
Read real stories of fraudulent ballots, harvesting schemes, and more in this new eBook.
The Heritage Guide to the Constitution
Receive a clause-by-clause analysis of the Constitution with input from more than 100 scholars and legal experts.
The Real Costs of America’s Border Crisis
Learn the facts and help others understand just how bad illegal immigration is for America.
More on This Issue
SPECIAL REPORT About an hour read
COMMENTARY 6 min read
SPECIAL REPORT 17 min read